NovoCure
NVCR
47 hedge funds and large institutions have $249M invested in NovoCure in 2015 Q4 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
47% more call options, than puts
Call options by funds: $2.96M | Put options by funds: $2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$124M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.8M |
| 3 |
HCM
Highline Capital Management
New York
|
+$34M |
| 4 |
Morgan Stanley
New York
|
+$10.3M |
| 5 |
Alkeon Capital Management
New York
|
+$8.96M |
Top Sellers
NVCR Hedge Fund Activity: Q4 2015 in Review
47 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2015, worth a combined $249M.
Buyers outnumbered sellers: 47 funds opened new NVCR positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $124M.
- 47 institutional investors held NovoCure (NVCR) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $249M of NovoCure stock for Q4 2015.
- 47 funds opened new NovoCure positions in Q4 2015 and 0 closed out, a net change of +47 holders.
- The largest NovoCure buyer in Q4 2015 was Fidelity Investments, an estimated $124M added.
Based on aggregated 13F filings for Q4 2015.